Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

2.3K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.3K
Inhaled Medications01:23

Inhaled Medications

1.1K
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
1.1K
Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

804
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
804
IV Infusion to Oral Dosing: Conversion Methods01:28

IV Infusion to Oral Dosing: Conversion Methods

212
The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.Pharmacokinetics of the...
212
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

368
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
368
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From global guidelines for cardio-kidney-metabolic diseases management to national implementation: perspectives from the guideline workshop taskforce.

Cardiovascular diabetology·2026
Same author

Potential Applications of Inhaled Insulin in Diabetic Ketoacidosis Prevention and During Exercise: Two Case Presentations.

Diabetes technology & therapeutics·2026
Same author

Unmet Needs in Insulin-Treated Diabetes Management.

Diabetes technology & therapeutics·2026
Same author

Role of Ultra-Rapid Acting Insulin in Managing Diabetes.

Diabetes technology & therapeutics·2026
Same author

Automated Insulin Delivery Is Beneficial in Adults With Insulin-Treated Type 2 Diabetes With and Without GAD65 Antibodies.

Diabetes care·2025
Same author

Role of Continuous Dual Glucose-Ketone Monitoring in Diabetes Care.

Diabetes technology & therapeutics·2025
Same journal

Continuous Glucose Monitoring Metrics and Perinatal Outcomes in Pregnant Women with Type 2 Diabetes.

Diabetes technology & therapeutics·2026
Same journal

Invited Commentary: Using Large Clinical Databases.

Diabetes technology & therapeutics·2026
Same journal

Impact of Technology Introduction on Glycemic Control of People Living with Type 1 Diabetes in Belgium: An Observational, Real-World Study.

Diabetes technology & therapeutics·2026
Same journal

Differences in Achieving Stringent Glycemic Targets Among Youth with Type 1 Diabetes: A SWEET Registry Study.

Diabetes technology & therapeutics·2026
Same journal

<i>Letter:</i> "Nocturnal Hypoglycemia: Characterization with Continuous Glucose Monitoring in a Real-World Setting".

Diabetes technology & therapeutics·2026
Same journal

Transient Benign Ketosis Is Common in Type 1 Diabetes During Very-Low Carbohydrate States: Novel Data from Continuous Ketone Sensor.

Diabetes technology & therapeutics·2026
See all related articles

Related Experiment Video

Updated: May 3, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.7K

Dosing Afrezza: It's Not that Complicated.

Steve V Edelman1, Thomas C Blevins2, Christopher G Parkin3

  • 1University of California San Diego, San Diego, California, USA.

Diabetes Technology & Therapeutics
|February 1, 2026
PubMed
Summary
This summary is machine-generated.

Afrezza inhaled insulin effectively manages blood sugar spikes after meals. Despite its availability, limited clinician awareness and dosing confusion hinder its adoption, requiring practical guidance for wider use.

Keywords:
delayed hypoglycemiahypoglycemiainhaled insulininsulin administrationinsulin dosingpostprandialtype 1 diabetestype 2 diabetes

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

42.1K
Ammonia Fiber Expansion AFEX Pretreatment of Lignocellulosic Biomass
09:30

Ammonia Fiber Expansion AFEX Pretreatment of Lignocellulosic Biomass

Published on: April 18, 2020

15.4K

Related Experiment Videos

Last Updated: May 3, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.7K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

42.1K
Ammonia Fiber Expansion AFEX Pretreatment of Lignocellulosic Biomass
09:30

Ammonia Fiber Expansion AFEX Pretreatment of Lignocellulosic Biomass

Published on: April 18, 2020

15.4K

Area of Science:

  • Pharmacology
  • Endocrinology
  • Diabetes Management

Background:

  • Afrezza inhaled insulin presents an alternative to traditional subcutaneous insulin delivery.
  • It offers rapid glucose control post-meal with reduced risk of delayed hypoglycemia.
  • Limited clinical adoption persists despite over a decade on the market.

Purpose of the Study:

  • To provide expert perspectives on optimizing Afrezza utilization.
  • To address barriers hindering Afrezza's widespread clinical adoption.
  • To offer practical guidance on Afrezza dosing, titration, patient selection, and education.

Main Methods:

  • Review of clinical data and expert experience with Afrezza.
  • Analysis of factors influencing clinician awareness and patient acceptance.
  • Development of practical strategies for effective Afrezza implementation.

Main Results:

  • Afrezza's unique pharmacokinetic profile aids postprandial glucose control.
  • Key barriers include lack of clinician awareness, dosing uncertainty, and safety/efficacy skepticism.
  • Clear dosing, titration, and patient education strategies are crucial.

Conclusions:

  • Afrezza is a valuable tool for managing postprandial hyperglycemia.
  • Overcoming adoption barriers requires enhanced clinician education and simplified practical guidelines.
  • Strategic patient selection and education can improve therapeutic outcomes with Afrezza.